228 related articles for article (PubMed ID: 25037196)
1. Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment.
Santilli F; Paloscia L; Liani R; Di Nicola M; Di Marco M; Lattanzio S; La Barba S; Pascale S; Mascellanti M; Davì G
J Am Heart Assoc; 2014 Jul; 3(4):. PubMed ID: 25037196
[TBL] [Abstract][Full Text] [Related]
2. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus.
Santilli F; Davì G; Consoli A; Cipollone F; Mezzetti A; Falco A; Taraborelli T; Devangelio E; Ciabattoni G; Basili S; Patrono C
J Am Coll Cardiol; 2006 Jan; 47(2):391-7. PubMed ID: 16412866
[TBL] [Abstract][Full Text] [Related]
3. Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost.
Lessiani G; Vazzana N; Cuccurullo C; Di Michele D; Laurora G; Sgrò G; Di Ruscio P; Simeone E; Di Iorio P; Lattanzio S; Liani R; Ferrante E; Davì G
Thromb Haemost; 2011 Feb; 105(2):321-8. PubMed ID: 21103664
[TBL] [Abstract][Full Text] [Related]
4. Significance of urinary 11-dehydro-thromboxane B
Simeone P; Boccatonda A; Liani R; Santilli F
Ageing Res Rev; 2018 Dec; 48():51-78. PubMed ID: 30273676
[TBL] [Abstract][Full Text] [Related]
5. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia.
Davi G; Alessandrini P; Mezzetti A; Minotti G; Bucciarelli T; Costantini F; Cipollone F; Bon GB; Ciabattoni G; Patrono C
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3230-5. PubMed ID: 9409316
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoids impair platelet thromboxane biosynthesis in community-acquired pneumonia.
Cangemi R; Carnevale R; Nocella C; Calvieri C; Cammisotto V; Novo M; Castellani V; D'Amico A; Zerbinati C; Stefanini L; Violi F;
Pharmacol Res; 2018 May; 131():66-74. PubMed ID: 29577968
[TBL] [Abstract][Full Text] [Related]
7. Myeloid-related protein-8/14 in acute coronary syndrome.
Sakuma M; Tanaka A; Kotooka N; Hikichi Y; Toyoda S; Abe S; Taguchi I; Node K; Simon DI; Inoue T
Int J Cardiol; 2017 Dec; 249():25-31. PubMed ID: 28986057
[TBL] [Abstract][Full Text] [Related]
8. Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor.
Ikonomidis I; Andreotti F; Nihoyannopoulos P
Heart; 2004 Apr; 90(4):389-93. PubMed ID: 15020512
[TBL] [Abstract][Full Text] [Related]
9. Determinants of thromboxane biosynthesis in patients with moderate to severe chronic kidney disease.
Vazzana N; Santilli F; Lattanzio S; Liani M; Giacci L; Del Rosso G; Salvati F; Boccatonda A; Ferroni P; Davì G
Eur J Intern Med; 2016 Sep; 33():74-80. PubMed ID: 27389698
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Nonplatelet Thromboxane Generation After Coronary Artery Bypass Graft Surgery.
Kakouros N; Nazarian SM; Stadler PB; Kickler TS; Rade JJ
J Am Heart Assoc; 2016 Mar; 5(3):e002615. PubMed ID: 27068626
[TBL] [Abstract][Full Text] [Related]
11. Predictors of thromboxane levels in patients with non-ST-elevation acute coronary syndromes on chronic aspirin therapy.
Niccoli G; Giubilato S; Leo A; Cosentino N; Fracassi F; Cataneo L; Porto I; Leone AM; Burzotta F; Trani C; Biasucci LM; Narducci ML; Pulcinelli FM; Crea F
Thromb Haemost; 2012 Jul; 108(1):133-9. PubMed ID: 22535468
[TBL] [Abstract][Full Text] [Related]
12. Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin.
Lattanzio S; Santilli F; Liani R; Vazzana N; Ueland T; Di Fulvio P; Formoso G; Consoli A; Aukrust P; Davì G
J Am Heart Assoc; 2014 Jul; 3(4):. PubMed ID: 25037197
[TBL] [Abstract][Full Text] [Related]
13. Determinants of platelet activation in human essential hypertension.
Minuz P; Patrignani P; Gaino S; Seta F; Capone ML; Tacconelli S; Degan M; Faccini G; Fornasiero A; Talamini G; Tommasoli R; Arosio E; Santonastaso CL; Lechi A; Patrono C
Hypertension; 2004 Jan; 43(1):64-70. PubMed ID: 14656953
[TBL] [Abstract][Full Text] [Related]
14. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Platelets; 2011; 22(3):188-95. PubMed ID: 21231857
[TBL] [Abstract][Full Text] [Related]
15. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo.
Landolfi R; Ciabattoni G; Patrignani P; Castellana MA; Pogliani E; Bizzi B; Patrono C
Blood; 1992 Oct; 80(8):1965-71. PubMed ID: 1327286
[TBL] [Abstract][Full Text] [Related]
16. Increased thromboxane biosynthesis in essential thrombocythemia.
Rocca B; Ciabattoni G; Tartaglione R; Cortelazzo S; Barbui T; Patrono C; Landolfi R
Thromb Haemost; 1995 Nov; 74(5):1225-30. PubMed ID: 8607099
[TBL] [Abstract][Full Text] [Related]
17. Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome.
Parker WAE; Orme RC; Hanson J; Stokes HM; Bridge CM; Shaw PA; Sumaya W; Thorneycroft K; Petrucci G; Porro B; Judge HM; Ajjan RA; Rocca B; Storey RF
Platelets; 2019; 30(2):148-157. PubMed ID: 30759035
[TBL] [Abstract][Full Text] [Related]
18. Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment.
Santilli F; Davì G; Basili S; Lattanzio S; Cavoni A; Guizzardi G; De Feudis L; Traisci G; Pettinella C; Paloscia L; Minuz P; Meneguzzi A; Ciabattoni G; Patrono C
J Thromb Haemost; 2010 May; 8(5):914-22. PubMed ID: 20180823
[TBL] [Abstract][Full Text] [Related]
19. Variation in thromboxane B2 concentrations in serum and plasma in patients taking regular aspirin before and after clopidogrel therapy.
Good RI; McGarrity A; Sheehan R; James TE; Miller H; Stephens J; Watkins S; McConnachie A; Goodall AH; Oldroyd KG
Platelets; 2015; 26(1):17-24. PubMed ID: 24433337
[TBL] [Abstract][Full Text] [Related]
20. Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype.
Vazzana N; Ganci A; Cefalù AB; Lattanzio S; Noto D; Santoro N; Saggini R; Puccetti L; Averna M; Davì G
J Am Heart Assoc; 2013 Apr; 2(2):e000063. PubMed ID: 23557750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
